Competition policies have at times been invoked to challenge possible cases of abuse of intellectual property rights (IPR). The Hazel Tau case in South Africa and the Dobfar case in the European Union (EU) are frequently cited examples in the area of medicines of how rules set up to help ensure that the market operates continue reading : Competition Policies and IPRs – Where to Look for Guidance given Policy Space